Navigation Links
Natural enzyme provides potential new approach for treating graft-vs.-host disease
Date:1/17/2012

ANN ARBOR, Mich. A natural enzyme derived from human blood plasma showed potential in significantly reducing the effects of graft-vs.-host disease, a common and deadly side effect of lifesaving bone marrow transplants.

Researchers from the University of Michigan Comprehensive Cancer Center looked at the drug alpha-1-antitrypsin, which is approved by the U.S. Food and Drug Administration for use in people who have a genetic mutation that makes them deficient in a certain enzyme. This drug has been used in many of these patients over extended periods of time and is known to cause minimal side effects.

More important, there are no known reports of increased susceptibility to infections. This is key for people with graft-vs.-host disease, where existing treatment options tend to suppress the immune system, putting patients at risk of infection. Graft-vs.-host disease is a major complication of bone marrow transplants using marrow from a donor, called an allogeneic transplant. This often-deadly side effect is what makes the procedure so risky.

"If we can get graft-vs.-host disease under control, we can more effectively use allogeneic bone marrow transplant to treat people with leukemia and lymphoma as well as other blood disorders. It would be a curative therapy for people who otherwise have no hope," says senior study author Pavan Reddy, M.D., associate professor of hematology/oncology at the U-M Medical School.

In this study, which appears in the Proceedings of the National Academy of Sciences, researchers used alpha-1-antitrypsin in mice that received allogeneic bone marrow transplants. The drug significantly reduced mortality from graft-vs.-host disease, compared to control mice who did not receive the drug.

In addition, alpha-1-antitrypsin reduced the number of inflammatory cells called T Effector cells that are known to be present in graft-vs.-host disease. It also increased the number of T-regulatory cells, which immunologists believe play a positive role in immune responses.

"It's likely the balance between the T-regulatory cells and the T Effector cells that leads to graft-vs.-host disease. Alpha-1-antitrypsin appears to have tipped that balance favorably," says lead study author Isao Tawara, M.D., Ph.D., a research investigator at the U-M Medical School.

The U-M researchers collaborated on this work with researchers from the University of Colorado and from Ben Gurion University of the Negev in Israel. The researchers are beginning to discuss a possible clinical trial using alpha-1-antitrypsin in post-transplant patients with graft-vs.-host disease for whom conventional therapies are no longer working.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Low levels of natural antibodies behind stroke
2. Whitemark Homes, Inc. Announces Corporate Update on Merger With Ribbon Naturals Corp.
3. Foamsource Introduces Natural Slumber 100% Natural Latex Mattresses & Toppers with Free Shipping
4. ThermaSkin Offers Free Natural Pepper Remedy To Acne Sufferers
5. Brooke Burke Named Spokeswoman for underWAY(TM), Americas First All Natural Appetite Suppressing Beverage & Thirst Quencher
6. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
7. Transcendental Meditation activates default mode network, the brains natural ground state
8. David Wolfe Hosts 3-Day Longevity Conference: Top Wellness Experts Reveal Tomorrow's Best Natural Health and Nutrition Information Today
9. Oram Plus Set to Take the Pain out of Gum Disease and Cavities, Naturally
10. Thrush Sufferers Seek Out Safe, Natural Remedies for Thrush, Driving a 237% Increase in Sales for "The 3 Day Thrush Cure"
11. 'Get Pregnant' Aims To Help Couples Conceive Naturally, Faster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... Diego, CA (PRWEB) , ... August 19, 2017 , ... ... and the KKK by saying there are two sides. There are not two sides ... a way to rationalize violence and prejudice, and the NPEIV stands against all forms ...
(Date:8/18/2017)... ... August 19, 2017 , ... Mr. ... presided over the Amazing Thailand Health and Wellness Tourism Showcase 2017 yesterday, which ... Pakprot, Deputy Governor for Tourism Products and Business at TAT said, “Thailand has ...
(Date:8/18/2017)... NY (PRWEB) , ... August 18, 2017 , ... ... of “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the ... available for individuals with hearing impairments and shares the latest innovations in hearing ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance Group, a Missouri-based insurance ... to generate community support for efforts to educate the local population on cancer realities ... types of cancer. , Each day in America, roughly 4,600 new cases of ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... assistance that serves communities throughout southern Florida, is working to support the Take ... to children from low income families. , The Take Stock In Children Foundation ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... 2017 Insightin Health, provider of data-driven ... engagement, announced the selection of Michael Wood ... effective as of February 2017. In this role, Wood ... for our clients. Wood brings with him more ... business analytics within the healthcare industry. Wood formerly ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc ... reached agreements to resolve virtually all known U.S. mesh ... discussions to resolve the known remaining U.S. claims at ... payments beginning in the fourth quarter of 2017 and ... of its second quarter 2017 results, the Company intends ...
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
Breaking Medicine Technology: